Innate immunity in lung transplantation

Innate immune pathways early after pulmonary transplantation have been shown to cause primary graft dysfunction (PGD) and also predispose to late graft failure. Recent studies in animal models have elucidated critical mechanisms governing such innate immune responses. Here, we discuss pathways of in...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of heart and lung transplantation Vol. 40; no. 7; pp. 562 - 568
Main Authors Shepherd, Hailey M., Gauthier, Jason M., Li, Wenjun, Krupnick, Alexander S., Gelman, Andrew E., Kreisel, Daniel
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2021
Subjects
Animals
cell death
damage-associated molecular patterns
graft rejection
Graft Rejection - immunology
Humans
Immunity, Innate
innate immunity
Lung Transplantation
Primary Graft Dysfunction - immunology
IRI
mtDNA
DAP12
HMGB1
CXCL2
MyD88
LPS
NF-κB
PRR
CLAD
innate immunity
RIPK1
TLR
graft rejection
cell death
MLKL
P2XR7
RIPK3
LMW-HA
STAT3
PKCδ
RAGE
IL-1β
PGD
PAMP
damage-associated molecular patterns
lung transplantation
MPTP
NET
TRIF
ATP
DAMP
Online AccessGet full text

Cover

More Information
Summary:Innate immune pathways early after pulmonary transplantation have been shown to cause primary graft dysfunction (PGD) and also predispose to late graft failure. Recent studies in animal models have elucidated critical mechanisms governing such innate immune responses. Here, we discuss pathways of inflammatory cell death, triggers for sterile and infectious inflammation, and signaling cascades that mediate lung injury early after transplantation. These studies highlight potential avenues for lung-specific therapies early following lung transplantation to dampen innate immune responses and improve outcomes.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ISSN:1053-2498
1557-3117
DOI:10.1016/j.healun.2021.03.017